Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.69 |
| ▸ | AR | P10275 | 3/20 | 0.60 |
| ▸ | DDB1 | Q16531 | 8/20 | 0.52 |
| ▸ | BTK | Q06187 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CDK9 | P50750 | 1/20 | 0.50 |
| ▸ | PLK4 | O00444 | 1/20 | 0.49 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.47 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31579239 | 0.94 | CRBN (0.63) | CRBNARDDB1BTKALDH1A1 | |
| SCHEMBL20231991 | 0.94 | CRBN (0.77) | CRBNARDDB1ALDH1A1CHRM2 | |
| SCHEMBL21983035 | 0.91 | CRBN (0.70) | CRBNARDDB1BTKALDH1A1 | |
| SCHEMBL31447732 | 0.91 | CRBN (0.80) | CRBNARDDB1BTKALDH1A1 | |
| SCHEMBL24421652 | 0.90 | CRBN (0.69) | CRBNARDDB1BTKALDH1A1 | |
| Hydrochloric Acid SCHEMBL29096741 | 0.90 | CRBN (0.69) | CRBNARDDB1BTKALDH1A1 | |
| SCHEMBL29132201 | 0.90 | CRBN (0.69) | CRBNARDDB1BTKALDH1A1 | |
| SCHEMBL29927999 | 0.90 | CRBN (0.69) | CRBNARDDB1BTKALDH1A1 | |
| Hydrochloric Acid SCHEMBL29710529 | 0.90 | CRBN (0.69) | CRBNARDDB1BTKALDH1A1 | |
| SCHEMBL30160860 | 0.90 | CRBN (0.74) | CRBNARDDB1BTKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161289-A1 | KAT6 Targeting Compounds | PRELUDE THERAPEUTICS INCORPORATED | 2025-05-22 | — | — | US | disclosed |
| EP-4539937-A1 | KAT6 TARGETING COMPOUNDS WITH UBIQUITIN LIGASE BINDING MOIETY | Prelude Therapeutics Incorporated (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023245150-A9 | KAT6 TARGETING COMPOUNDS WITH UBIQUITIN LIGASE BINDING MOIETY | PRELUDE THERAPEUTICS INCORPORATED (US) | 2025-01-16 | — | — | WO | disclosed |
| US-20230416240-A1 | KAT6 TARGETING COMPOUNDS | PRELUDE THERAPEUTICS, INCORPORATED | 2023-12-28 | — | — | US | disclosed |
| WO-2023245150-A1 | KAT6 TARGETING COMPOUNDS WITH UBIQUITIN LIGASE BINDING MOIETY | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023245150-A1 | KAT6 TARGETING COMPOUNDS WITH UBIQUITIN LIGASE BINDING MOIETY | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416240-A1 | KAT6 TARGETING COMPOUNDS | KAT6A, KAT6B, KAT2A | CRBN 645/4885AR 699/4885DDB1 234/4885 |
| US-20250161289-A1 | KAT6 Targeting Compounds | KAT6A, KAT6B, KAT2A | CRBN 645/4885AR 699/4885DDB1 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.